As investors look toward 2026, market analysts at Nuvama have highlighted a select group of stocks poised for significant growth. Among the top recommendations is Dr Lal PathLabs, which has received a renewed 'Buy' rating from the firm.
The brokerage firm has bolstered its confidence in the diagnostic chain, revising the target price to Rs 2,140 from a previous level of Rs 1,900. This upward adjustment suggests a promising upside of approximately 21% from current trading levels.
Alongside the healthcare sector, the firm has included IDFC First Bank in its curated list of long-term opportunities. The selection is based on robust fundamentals and favorable market positioning aimed at generating double-digit returns.
Key performance expectations include:
- Potential returns ranging between 10% and 30% for the selected portfolio.
- Strategic focus on companies demonstrating consistent long-term demand.
- Sector-specific tailwinds driving valuation growth through 2026.
